Gapping up
In reaction to strong earnings/guidance:
- KBH +6.1%, AIR +3.2%, KMX +2.4%
M&A news:
- NLSN +2.2% (attributed to PE interest)
Other news:
- ALDX +55.6% (extended higher after confirming it will host call Sept 26 at 8am ET to provide the results from its dry eye disease Phase 2b clinical trial)
- EGY +15.8% (granted 10 year extension of Exclusive Exploitation Authorizations in the Etame Marin Permit)
- VSTM +9.8% (Verastem and CSPC Pharmaceutical Group enter into exclusive licensing agreement for the development and commercialization of COPIKTRA in China)
- VNDA +4.8% (ticking higher; to join S&P SmallCap 600)
- AUPH +3.1% (higher after completing enrollment for AURORA Phase 3 trial ahead of schedule)
- IGT +2% (Intl Game Tech and William Hill US (WIMHY unit) entered into multi-year agreement to offer US lotteries a full service solution for sports betting)
- GLOP +2% (to sell 2,250,000 common units at a price of $23.60 per common unit to funds managed by Tortoise Capital Advisors for gross proceeds of $53.1 million)
- ZLAB +1.8% (presents results of its open-label study to evaluate the pharmacokinetic profile of ZL-2306)
- ANAB +1.6% (prices offering of 2.2 mln shares of common stock at $94.46 per share)
- PHM +1.4% (in sympathy with KBH)
- AINC +1.3% (prices offering of 270,000 shares of common stock at $74.50 per share)
- PTLA +1.1% (ticking higher; FDA has granted Orphan Drug Designation to cerdulatinib)
- TOL +1% (in sympathy with KBH)
Analyst comments:
- GPRO +5.3% (upgraded to Outperform from Perform at Oppenheimer)
- IBM +1.6% (upgraded to Buy from Neutral at UBS)
- MTB +1.4% (upgraded to Buy from Neutral at Goldman)
- VIAB +1.4% (upgraded to Buy from Neutral at B. Riley FBR)
- LNG +1.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- FCFS +1% (initiated with a Overweight at Barclays)
- GOOS +0.9% (initiated with a Buy at DA Davidson)
- TJX +0.6% (initiated with a Buy at DA Davidson)
![]()